Bacillus calmette-guerin substrain tice live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Bacillus calmette-guerin substrain tice live antigen is a live attenuated vaccine against Mycobacterium bovis.

Brand Names
BCG Vaccine, Tice Bcg
Generic Name
Bacillus calmette-guerin substrain tice live antigen
DrugBank Accession Number
DB10343
Background

Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • BCG, Live, Tice Strain

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prophylaxis ofTa papillary tumors following transurethral resection••••••••••••
Prevention ofTuberculosis••••••••••••
Treatment ofCarcinoma in situ of the urinary bladder••••••••••••
Prophylaxis ofCarcinoma in situ of the urinary bladder••••••••••••
Prophylaxis ofStage t1 papillary tumors following transurethral resection••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Bacillus calmette-guerin substrain tice live antigen.
Adefovir dipivoxilThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adefovir dipivoxil.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bcg VaccineInjection, powder, lyophilized, for solution50 mg/1PercutaneousMerck Sharp & Dohme Llc1989-06-21Not applicableUS flag
OncoticePowder, for solution50 mg/1IntravesicalMerck Ltd.1995-12-31Not applicableCanada flag
Tice BcgPowder, for suspension50 mg/50mLIntravesicalMerck Sharp & Dohme Llc1990-08-24Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2XQ558L16Z
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910522
RxNav
221050

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionPercutaneous50 mg/1
Injection, powder, for suspensionIntravesical50 mg
Powder, for solutionIntravesical50 mg/1
Powder, for suspensionIntravesical50 mg/50mL
Injection, powder, lyophilized, for suspension50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:03 / Updated at April 19, 2024 20:55